secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-007042
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed FY2022 net loss $56.8M; cash $142.1M; key MM-120 data readouts expected late 2023
--------------------------------------------------------------------------------

- Net loss of $56.8M, improved from $93.0M in FY2021; no revenue (clinical-stage biopharma).
- Cash and equivalents $142.1M vs $133.5M; cash runway into first half 2025.
- R&D expenses $36.2M (up $1.4M); G&A $30.2M (down $28.9M, largely due to lower stock comp).
- Phase 2b MM-120 GAD top-line data and Phase 2a MM-120 ADHD data both expected late 2023.
- First clinical trial of MM-402 (R-MDMA for autism) planned for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/0000950170-23-007042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/mnmd-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer